ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sinocelltech Group Limited clinical trials

Part of Lhasa Ailike Investment Consulting Co., Ltd., which holds 62.98% as of 2026-05-15. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 82 studies whose lead sponsor is Sinocelltech Group Limited or the company grouped under it. 33 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 10, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Compare Sinocelltech Group with Merck and GlaxoSmithKline →

Pipeline: 13 programs

Each counted once: 13 with a study Sinocelltech Group Limited leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 4 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Sinocelltech Group Limited’s own registered studies; Sinocelltech Group Limited’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Sinocelltech Group Limited’s studies test, most open studies first — 14 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 4 more

Coming up

10 of Sinocelltech Group Limited’s studies under way reach primary completion within a year, 2 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. 1M
  6. 2A
  7. 1M
  8. J
  9. 2J
  10. A
  11. 3S
  12. O
  13. 1N

Add all 10 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 19, 2026.

All 82 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now3340%Not yet recruiting 17 · Recruiting 16
  • Under way, not recruiting34%
  • Completed67%
  • Stopped early56%Withdrawn 3 · Terminated 2
  • Status unknown or other3543%

Phase

  • Phase 245
  • Phase 136
  • Phase 324
  • Phase 41

Where

  • China50
  • United Arab Emirates3
  • Turkey2
  • Colombia1
  • Brazil1
  • Peru1

Over the years

  1. 12
  2. 13
  3. 14
  4. 15
  5. 16
  6. 17
  7. 18
  8. 19
  9. 20
  10. 21
  11. 1222
  12. 23
  13. 24
  14. 25
  15. 1126

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Sinocelltech Group Limited.

  • Sinocelltech Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    82 studies →

Focus areas

Conditions Sinocelltech Group Limited leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 82. Browse all 82 →